

Press Release

Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023

January 8, 2024 – release at 7:30 am CET
Sophia Antipolis, France

Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st, 2023:

- 311,067 shares
- € 8,541.77
- Number of executions on buy side on semester: 92
- Number of executions on sell side on semester: 68
- Traded volume on buy side on semester: 27,902 shares for € 11,261.43
- Traded volume on sell side on semester: 21,402 shares for € 9,043.82

As a reminder:

- the following resources appeared on the last half year statement on June 30, 2023 on the liquidity account:
 - 304,567 shares
 - € 10,640.56
 - Number of executions on buy side on semester: 128
 - Number of executions on sell side on semester: 111
 - Traded volume on buy side on semester: 74,584 shares for € 62,919.32
 - Traded volume on sell side on semester: 58,982 shares for € 51,368.57
- the following resources appeared on the liquidity account when the activity started:
 - 0 shares
 - € 500,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd, 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

On January 3, 2024, Nicox announced the termination of the liquidity contract dated August 3rd, 2020 entered into with Kepler Cheuvreux, effective as of January 1st, 2024.

Nicox Corporate Status Update

The Company is currently funded until the end of June 2024, exclusively on the basis of the development of NCX 470. The Company is pursuing licensing discussions which could extend the cash runway. In parallel, the Company is exploring multiple strategic options and is also discussing with its creditors to restructure its debt.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	92	27,902	11,261.43	68	21,402	9,043.82
03/07/2023	1	300	141.00	-	-	-
07/07/2023	4	1,200	540.00	-	-	-
10/07/2023	10	3,000	1,350.00	8	2,400	1,224.00
07/08/2023	2	300	126.00	-	-	-
22/08/2023	1	1,000	430.00	-	-	-
23/08/2023	6	1,000	440.00	1	300	132.00
24/08/2023	3	1,000	440.00	-	-	-
25/08/2023	2	500	220.00	-	-	-
28/08/2023	1	235	101.05	-	-	-
29/08/2023	1	765	328.95	-	-	-
01/09/2023	-	-	-	1	1,000	440.00
14/09/2023	1	1,000	420.00	-	-	-
20/09/2023	1	1	0.42	1	1	0.42
26/09/2023	2	301	123.41	1	1	0.42
04/10/2023	2	300	120.00	-	-	-
05/10/2023	5	2,000	740.00	-	-	-
09/10/2023	-	-	-	2	300	114.00
10/10/2023	1	300	108.00	-	-	-
12/10/2023	-	-	-	1	1	0.40
17/10/2023	1	100	36.00	1	500	185.00
25/10/2023	2	1,000	330.00	-	-	-
26/10/2023	5	1,455	436.50	2	500	170.00
27/10/2023	1	300	93.00	2	300	99.00
30/10/2023	1	445	133.50	-	-	-
31/10/2023	-	-	-	5	1,700	595.00
01/11/2023	-	-	-	12	3,799	1,595.58
02/11/2023	-	-	-	1	300	144.00
03/11/2023	-	-	-	1	300	141.00
06/11/2023	1	300	138.00	-	-	-
07/11/2023	1	300	132.00	-	-	-
08/11/2023	-	-	-	1	300	141.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
09/11/2023	2	300	132.00	-	-	-
13/11/2023	6	2,200	946.00	-	-	-
14/11/2023	2	300	126.00	2	300	129.00
15/11/2023	3	900	369.00	-	-	-
16/11/2023	-	-	-	3	900	378.00
17/11/2023	1	300	120.00	-	-	-
23/11/2023	1	500	205.00	-	-	-
24/11/2023	1	300	120.00	-	-	-
27/11/2023	6	1,560	608.40	-	-	-
28/11/2023	3	500	195.00	4	1,000	400.00
29/11/2023	1	500	195.00	-	-	-
01/12/2023	1	440	167.20	-	-	-
04/12/2023	-	-	-	1	500	200.00
05/12/2023	3	500	190.00	-	-	-
06/12/2023	1	500	185.00	1	500	190.00
08/12/2023	-	-	-	2	500	195.00
12/12/2023	1	500	190.00	-	-	-
18/12/2023	-	-	-	4	500	195.00
19/12/2023	4	1,000	390.00	-	-	-
21/12/2023	1	500	195.00	-	-	-
22/12/2023	-	-	-	7	3,500	1,505.00
28/12/2023	-	-	-	1	500	210.00
29/12/2023	-	-	-	3	1,500	660.00

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIAE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.

For more information www.nicox.com.

Analyst coverage

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox

Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in section 2.7 of the "Rapport Annuel 2022" and in section 4 of the "Rapport semestriel financier et d'activité 2023" which are available on Nicox's website (www.nicox.com).

Nicox SA

Drakkar 2 - Bât D
2405 route des Dolines
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99